Eli Lilly and Company
893 S Delaware St
Indianapolis
Indiana
46285
United States
Tel: 317-276-2000
Website: http://www.lilly.com/
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to make life better for people around the world. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities through philanthropy and volunteerism. We also have been committed to investing in our employees – through competitive salaries, training and development, health, and the opportunity to do good. The pharmaceutical industry is a complex, rapidly changing environment and we’re looking for people who are determined to make life better for people around the world. Visit https://careers.lilly.com for more information.
Stock Symbol: LLY
Stock Exchange: NYSE
We discover life-changing medicines. We commit to diversity and inclusion. We volunteer millions of hours. We make life better. We are Lilly.
2244 articles with Eli Lilly and Company
-
Lilly to Participate in Barclays Global Healthcare Conference
3/8/2019
Eli Lilly and Company will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2019.
-
Lilly Announces Final Exchange Ratio of 4.5121 for Elanco Exchange Offer
3/7/2019
Eli Lilly and Company (NYSE: LLY) today announced the final exchange ratio for its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYSE: ELAN) owned by Lilly.
-
Lilly to Participate in Cowen Health Care Conference
3/7/2019
Eli Lilly and Company will participate in the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019.
-
Lilly Receives FDA Priority Review Designation for Emgality® (galcanezumab-gnlm) Injection for the Preventive Treatment of Episodic Cluster Headache in Adults
3/5/2019
Eli Lilly and Company announced that the U.S. Food and Drug Administration has granted Priority Review for its supplemental Biologics License Application for Emgality® injection for the preventive treatment of episodic cluster headache in adults.
-
Lilly to Introduce Lower-Priced Insulin
3/4/2019
Authorized generic version of Humalog will be available in U.S. pharmacies at 50 percent lower list price
-
According to a recent BioSpace survey, 70% of life science employers indicated their company anticipates an increase in the number of open positions during 2019. So if you are on the job hunt, keep your eye out for new positions posted throughout the year!
-
In what is likely a preemptive move to avoid government action on insulin prices, Eli Lilly announced it will start selling an “authorized generic” version of Humalog 100 at about 50 percent off the list prices.
-
Lilly to Present Data Demonstrating Continued Scientific Advancements in Broad Dermatology Portfolio at AAD Annual Meeting
3/1/2019
Over 25 abstracts for medicines in Lilly's dermatology portfolio, including Taltz® (ixekizumab), highlight new findings for the treatment of patients with moderate-to-severe plaque psoriasis, including genital psoriasis and active psoriatic arthritis
-
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
-
Ethisphere announced its 13th Annual World’s Most Ethical Companies list and one biopharmaceutical company made it—Eli Lilly & Co.
-
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
2/19/2019
Pfizer Inc. and Eli Lilly and Company announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain.
-
When your back hurts, your whole body hurts. This morning, Pfizer and Eli Lilly reported positive results from its Phase III back pain treatment tanezumab.
-
Lilly Completes Acquisition of Loxo Oncology
2/15/2019
Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Loxo Oncology, Inc. (NASDAQ:LOXO).
-
Lilly To Participate in Leerink Partners Global Healthcare Conference
2/14/2019
Eli Lilly and Company will participate in the Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019.
-
Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride
2/14/2019
Tradjenta (linagliptin) demonstrated no increased cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk
-
Lilly Will Initiate Divestiture of its Remaining Interest in Elanco Animal Health
2/8/2019
Provides Lilly shareholders opportunity for tax-free exchange
-
Lilly to Participate in Guggenheim Healthcare Talks Idea Forum
2/8/2019
Eli Lilly and Company (NYSE:LLY) will participate in the Guggenheim Healthcare Talks Idea Forum on Thursday, February 14, 2019. Anne White, president of Lilly Oncology, and Levi Garraway, M.D., Ph.D., senior vice president, oncology research and development, will participate in a fireside chat at 1:00 p.m., Eastern Time.
-
After Health and Human Services Secretary Alex Azar, a former executive with Eli Lilly, unveiled a pricing reform that would allow pharma companies to end the rebate system and pass those savings directly to consumers, leaders from across the pharma industry are offering early support for the pro...
-
Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology
2/6/2019
Eli Lilly and Company (NYSE: LLY) announced financial results for the fourth quarter and full year of 2018.
-
Like many other big pharma companies, Eli Lilly & Co. reported a good 2018 with a less optimistic view of 2019. Fourth-quarter 2018 revenue grew by 5 percent, driven by newer drugs. Operating expenses also went up by a percentage point. Full-year 2018 revenue grew by 7 percent to $24.556 billion.